Real World Evidence Clinical Utility Study of KidneyIntelX
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age23+
SponsorRenalytix AI, Inc.
About this trial
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
Eligibility criteria
Qualifiers
Individuals with Type 2 diabetes and concurrent chronic (diabetic) kidney disease (G3a-G3b or G1-G2, A2-A3) per KDIGO CKD staging.
Disqualifiers
Patents without the appropriate characteristics as identified in the KidneyIntelX intended use population.
Patients with eGFR <30 or ≥ 60 ml/min/1.73m2 without albuminuria.
Patients with ESRD or on renal recovery treatments at time of enrollment.
Patients who are pregnant at the time of enrollment.
Trial design
Treatments tested in this trial
- KidneyIntelX
Treatment groups
No treatment groups listed
Sponsors and collaborators
Renalytix AI, Inc.
Lead sponsor
Mount Sinai Hospital, New York
Collaborator
Source ClinicalTrials.gov